

**AMENDMENTS TO THE CLAIMS**

Please cancel claim 103 without prejudice. Please amend claims 75, 93, and 98-99. This listing of claims replaces all previous versions and listings of claims.

**Listing of Claims:**

1-74. **(Canceled)**

75. **(Currently amended)** A method for determining whether a subject is likely to have a colon neoplasm comprising:

- a) obtaining a biological sample from said subject; and
- b) detecting in the biological sample at least one secreted ColoUp2 polypeptide selected from the group consisting of: a) (i) a secreted polypeptide produced by the expression of the nucleic acid having the ~~amino~~ nucleic acid sequence of SEQ ID ~~No~~ NO: 5, and b) (ii) a secreted polypeptide having the amino acid sequence of SEQ ID ~~No~~ NO: 3, wherein the presence of said at least one secreted ColoUp2 polypeptide indicates that the subject is likely to have a colon neoplasm.

76-83. **(Canceled)**

84. **(Previously presented)** The method of claim 75, wherein the biological sample is a whole blood sample or a fraction derived from blood.

85. **(Previously presented)** The method of claim 84, wherein the biological sample is selected from among blood plasma and blood serum.

86. **(Original)** The method of claim 75, wherein the biological sample is derived from the inner wall and/or lumen of the intestinal tract.

87. **(Previously presented)** The method of claim 75, wherein the biological sample is a stool sample.

88. **(Original)** The method of claim 75, wherein the biological sample is a urine sample.

89. **(Original)** The method of claim 75, wherein the polypeptide is detected by an assay that employs an antibody.
90. **(Previously presented)** The method of claim 89, wherein the assay is selected from among: an immunoprecipitation assay, a Western blot, a radioimmunoassay and an enzyme-linked immunosorbent assay (ELISA).
91. **(Previously presented)** The method of claim 89, wherein the assay comprises contacting the biological sample with an antibody that interacts with secreted ColoUp2 polypeptide.
92. **(Canceled)**
93. **(Currently amended)** The method of claim 89, wherein the antibody interacts with an epitope of the amino acid sequence of SEQ ID NO: 3.
94. **(Previously presented)** The method of claim 89, wherein the antibody interacts with an epitope of said polypeptide produced by the expression of the nucleic acid sequence set forth in SEQ ID NO: 5.
95. **(Original)** The method of claim 89, wherein the antibody is detectably labeled.
96. **(Original)** The method of claim 95, wherein the label is selected from the group consisting of an enzyme, a fluorescent substance, a chemiluminescent substance, a chromophore, a radioactive isotope and a complexing agent.
97. **(Previously presented)** The method of claim 75, further comprising determining the amount of said at least one secreted ColoUp2 polypeptide in the biological sample.
98. **(Currently amended)** The method of claim ~~75~~ 97, wherein the method further comprises:  
(a) determining the amount of said at least one secreted ColoUp2 polypeptide in the biological sample from said subject;  
(b) determining the amount of said at least one secreted ColoUp2 polypeptide in a biological sample obtained from a different, normal control subject; and  
(c) comparing the amount ~~[[s]] of the secreted ColoUp2 polypeptide~~ from step (a) in said samples to the amount from step (b).

99. **(Currently amended)** The method of claim ~~75~~ 97, wherein the method further comprises:  
(a) determining the amount of said at least one secreted ColoUp2 polypeptide in the biological sample from said subject; and  
(b) comparing the amount from step (a) to an amount determined from said subject in the past.
100. **(Previously presented)** The method of claim 75, wherein the colon neoplasm is a colon adenoma or a colon cancer.
101. **(Previously presented)** The method of claim 75, wherein the presence of said at least one secreted ColoUp2 polypeptide aids in determining the therapeutic protocol to be administered to a subject likely to have colon neoplasia.
102. **(Original)** The method of claim 75, wherein the subject was not previously diagnosed with colon cancer.
103. **(Canceled)**
104. **(Previously presented)** The method of claim 75, wherein the colon neoplasm is a colon adenoma.
105. **(Previously presented)** The method of claim 75, wherein the colon neoplasm is colon cancer.
106. **(Previously presented)** The method of claim 75, wherein the colon neoplasm is metastatic colon cancer.
- 107-122. **(Canceled)**
123. **(Previously presented)** The method of claim 75, wherein the polypeptide produced by the expression of the nucleic acid sequence of SEQ ID NO: 5 is a polypeptide having the sequence of SEQ ID NO: 21.

124.     **(Previously presented)** The method of claim 75, wherein the polypeptide produced by the expression of the nucleic acid sequence of SEQ ID NO: 5 is a polypeptide having the sequence of SEQ ID NO: 3.

125.     **(Canceled)**